A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · DOUBLE
- Evidence population
- Human clinical study registration
- Participants
- 160
- Population
- ALL · 18 Years to 70 Years
- Duration
- 2026-01-01 to 2026-12-01
- Intervention
- hypoglycemic treatment; Tangshen'an Granules; Ginkgo Leaf Tablets; Mecobalamin Tablets; placebo
- Comparator
- Control Group
- Outcomes measured
- Retinal Nerve Fiber Layer Thickness (RNFL) — From the date of randomization until the end of the 24-week intervention p…; Foveal Avascular Zone (FAZ) — From the date of randomization until the end of the 24-week intervention period; Visual Evoked Potential (VEP) — From the date of randomization until the end of the 24-week intervention period; Gray matter volume (GMV) — From the date of randomization until the end of the 24-week intervention period; Montreal Cognitive Assessment（MoCA）score — From the date of randomization until the end of the 24-week intervention per…; Mini - Mental State Examination（MMSE）score — From the date of randomization until the end of the 24-week intervention p…; Symptom scores in traditional Chinese medicine — From the date of randomization until the end of the 24-week interventi…; Glucose metabolism indicators:Hemoglobin A1c (HbA1c) — From the date of randomization until the end of the 24-week inte…; Glucose metabolism indicators:Fasting blood glucose — From the date of randomization until the end of the 24-week inter…; Quality of Life Scale (SF-36) — From the date of randomization until the end of the 24-week intervention period
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Blood-brain barrier ageing · 100%Title contains controlled term: neurovascular. Abstract contains controlled term: neurovascular. Source terminology contains: neurovascular. Title supplies longevity context: aging. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.